Humana (NYSE:HUM) Price Target Raised to $301.00

Humana (NYSE:HUM) had its target price raised by Morgan Stanley from $288.00 to $301.00 in a report released on Tuesday morning,Benzinga reports. They currently have an equal weight rating on the insurance provider’s stock.

Several other equities research analysts have also commented on HUM. TD Cowen increased their price objective on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Wells Fargo & Company decreased their price target on Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Truist Financial cut their price objective on Humana from $400.00 to $260.00 and set a “hold” rating on the stock in a research report on Friday, October 11th. Jefferies Financial Group lowered Humana from a “buy” rating to a “hold” rating and decreased their target price for the company from $519.00 to $253.00 in a research report on Monday, October 7th. Finally, Leerink Partnrs downgraded shares of Humana from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Twenty equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $300.50.

Humana Stock Down 1.7 %

Shares of NYSE:HUM opened at $235.78 on Tuesday. The business’s 50 day moving average is $274.01 and its 200 day moving average is $321.71. Humana has a 12-month low of $213.31 and a 12-month high of $475.00. The stock has a market cap of $28.39 billion, a price-to-earnings ratio of 20.88, a PEG ratio of 2.15 and a beta of 0.53. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The firm had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. On average, sell-side analysts forecast that Humana will post 16.14 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.50%. The ex-dividend date is Tuesday, December 31st. Humana’s dividend payout ratio is 31.36%.

Institutional Investors Weigh In On Humana

Several hedge funds have recently bought and sold shares of HUM. Raymond James & Associates raised its position in Humana by 5.2% in the 2nd quarter. Raymond James & Associates now owns 96,189 shares of the insurance provider’s stock worth $35,941,000 after purchasing an additional 4,757 shares during the period. Fifth Third Bancorp increased its holdings in shares of Humana by 41.7% in the second quarter. Fifth Third Bancorp now owns 10,659 shares of the insurance provider’s stock worth $3,983,000 after buying an additional 3,135 shares during the period. Fifth Third Wealth Advisors LLC bought a new stake in shares of Humana in the 2nd quarter valued at about $549,000. Private Advisory Group LLC purchased a new stake in Humana during the 2nd quarter valued at about $7,293,000. Finally, &PARTNERS bought a new position in Humana during the 2nd quarter worth approximately $380,000. 92.38% of the stock is currently owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.